The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

If you have metastatic non-small-cell lungcancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

Living with stage 4 NSCLC can feel scary. However, encouraging treatment developments are helping people live longer and enjoy a better quality of life. A 2020 research review even states that new ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of lung cancer cases.

By identifying specific mutations in lung cancer, doctors can develop more effective NSCLC treatment plans ... Healthline has strict sourcing guidelines and relies on peer-reviewed studies ...

Lung cancer is the leading cause of cancer-related deaths in the United States, with NSCLC accounting for up to 85% of diagnoses. While surgery has been a primary treatment option for some early ...

for the treatment of non-small cell lung cancer (NSCLC). According to InvestingPro data, the company maintains a strong balance sheet, holding more cash than debt, which provides financial ...